ZENTALIS PHARMACEUTICALS

Contributing Author

Recent Articles by ZENTALIS PHARMACEUTICALS

Nov-10	Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress ZNTL GlobeNewswire
Nov-03	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
Nov-03	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences ZNTL GlobeNewswire
Oct-13	Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ZNTL GlobeNewswire
Oct-01	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
Sep-02	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
Aug-28	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences ZNTL GlobeNewswire
Aug-26	Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary ZNTL GlobeNewswire
Aug-06	Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress ZNTL GlobeNewswire
Jul-01	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
Jun-02	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire
May-14	Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress ZNTL GlobeNewswire
May-01	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ZNTL GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.